The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).

Compounds of formula (I) useful as metalloproteinase inhibitors especially as inhibitors of MMP 13.

Un compuesto de fórmula I como un enanti6mero individual o en una forma enriquecida en un enantiómero en la que Het es y X es un halógeno F Cl Br o I; NO2 N2+ o -OSO2R en el que R es CH3 CF3 p-tolueno m-clorobenceno o p-clorobenceno; y sus tautómeros.

Disclosed herein are piperidine derivatives of formula (Ia) wherein the substituents are as defined within the specification processes for their preparation pharmaceutical compositions containing said compounds as the active ingredient their use as medicaments and their use in the manufacture of medicaments for the treatment of bacterial infections such as community-acquired pneumonia hospital-acquired pneumonia skin and skin structure infections acute exacerbation of chronic bronchitis acute si...

Compounds of general formula: as well as salts enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy in particular in the management of pain depression and anxiety.

The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.

The present invention relates to a new process for the preparation of new crystal modifications of esomeprazole non-salt form. Further the present invention also relates to the use of said new crystal modifications for the treatment of gastrointestinal disorders pharmaceutical compositions containing them as well as the crystal modifications as such.